Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Clin Nucl Med. 2013 Apr;38(4):256-62. doi: 10.1097/RLU.0b013e3182816318.
The objectives of this study were to determine if the baseline SUVmax measured by F-FDG PET/CT correlates with molecular subtype and to explore the impact of baseline SUVmax on the survival of patients with metastatic breast cancer (MBC).
Patients with MBC were screened with PET/CT from February 2007 until December 2010. Multivariate linear regression analysis was performed to identify independent variable correlation with SUVmax. Prognostic variables identified by univariate analysis, with P < 0.1, were analyzed in the multivariate Cox model.
A total of 244 MBC patients were eligible for this study. Multivariate linear regression analysis showed that molecular subtype, visceral metastasis, and number of metastatic organs could be used to predict the logarithmic values of SUVmax (lgSUVmax) for previous untreated MBC patients, whereas for those with 1 or more line previous treatment, the number of metastatic organs was identified as the only independent variable correlating with lgSUVmax. Cox regression analysis indicated that only in patients with previously untreated MBC did baseline SUVmax (continuous variable) act as an independent prognostic factor (hazard ratio = 1.049 for progression-free survival, 1.124 for overall survival).
Baseline SUVmax correlates with molecular subtypes only in previously untreated MBC patients. PET/CT imaging can be used as a potential prognostic tool for patients with newly diagnosed MBC.
本研究旨在确定 F-FDG PET/CT 检测的基线 SUVmax 是否与分子亚型相关，并探讨基线 SUVmax 对转移性乳腺癌（MBC）患者生存的影响。
2007 年 2 月至 2010 年 12 月，对 MBC 患者进行了 PET/CT 筛选。采用多元线性回归分析确定与 SUVmax 相关的独立变量。采用单因素分析确定有意义的预后变量（P<0.1），并在多因素 Cox 模型中进行分析。
共 244 例 MBC 患者符合本研究标准。多元线性回归分析显示，分子亚型、内脏转移和转移器官数量可用于预测未经治疗的 MBC 患者的 SUVmax 对数（lgSUVmax）值，而对于 1 线或更多线治疗后的患者，只有转移器官数量被确定为与 lgSUVmax 相关的唯一独立变量。Cox 回归分析表明，仅在未经治疗的 MBC 患者中，基线 SUVmax（连续变量）是独立的预后因素（无进展生存期的危险比为 1.049，总生存期的危险比为 1.124）。
基线 SUVmax 仅与未经治疗的 MBC 患者的分子亚型相关。PET/CT 成像可作为新诊断的 MBC 患者的潜在预后工具。
